Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
Appl Radiat Isot
; 96: 91-101, 2015 Feb.
Article
in En
| MEDLINE
| ID: mdl-25479439
ABSTRACT
We evaluated and compared a new bombesin analog [Tyr-Gly5, Nle(14)]-BBN(6-14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC-3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTA-peptide to PC-3 cells was observed. Both peptides could target PC-3 and LNCaP tumors in vivo and both tumor types could be visualized by microSPECT/CT.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Breast Neoplasms
/
Bombesin
/
Receptors, Bombesin
/
Radiopharmaceuticals
/
Pentetic Acid
/
Heterocyclic Compounds, 1-Ring
Type of study:
Evaluation_studies
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
En
Journal:
Appl Radiat Isot
Journal subject:
MEDICINA NUCLEAR
/
SAUDE AMBIENTAL
Year:
2015
Document type:
Article